MoneyShow presents top investment ideas for 2026 from leading advisors. Part 1 includes AbbVie, Alexandria Real Estate ...

Lynk Pharmaceuticals’ next generation JAK inhibitor, zemprocitinib, has met its primary and secondary trial endpoints during a Phase III study in rheumatoid arthritis. Image credit: one photo via ...

Both Skyrizi and its cousin Rinvoq have landed in the annual top three, in varying positions, since 2022. That was once again the case in 2025, when Skyrizi retained its place at the top and Rinvoq ...

Josef Newgarden returns to the center stage at Fox Sports marketing ahead of the 2026 season, with the first in their ...

AbbVie continues to project low single-digit growth through 2030 as it expands its immunology franchise and makes a major ...

You don't have to look very hard to find dividend stocks, particularly among established, stable companies. In fact, Charles Schwab estimates that 80% of the companies represented in the S&P 500 are ...

Ointment cream being applied on a right hand's thumb with eczema. Eczema, also known as atopic dermatitis, is a chronic inflammatory skin condition that affects millions of children and adults. It ...

AbbVie ABBV and AstraZeneca AZN are both global healthcare companies with diversified drug portfolios. Both companies have strong leadership positions in immunology and oncology areas. While AbbVie ...

Earlier in December 2025, OSE Immunotherapeutics amended its partnership with AbbVie over the inflammatory disease candidate ABBV-230, with OSE taking back control of preclinical and Phase 1 work, at ...

AbbVie is a Dividend King that successfully navigated a challenging patent cliff. Coca-Cola is a household name that has survived and thrived for 139 years. Realty Income has increased its dividend ...